Search

Pacira Pharmaceuticals Inc-DE

Cerrado

SectorSanidad

25.41 2.71

Resumen

Variación precio

24h

Actual

Mínimo

24.44

Máximo

25.54

Métricas clave

By Trading Economics

Ingresos

1.7M

4.7M

Ventas

15M

192M

P/B

Media del Sector

71.029

57.366

BPA

0.44

Margen de beneficios

2.418

Empleados

825

EBITDA

-3.9M

26M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+12.81% upside

Dividendos

By Acuity

Próximas Ganancias

5 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-68M

991M

Apertura anterior

22.7

Cierre anterior

25.41

Noticias sobre sentimiento de mercado

By Acuity

51%

49%

293 / 340 Clasificación en Healthcare

Pacira Pharmaceuticals Inc-DE Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 ago 2026, 19:56 UTC

Pacira Biosciences Inc. shares are higher during Friday's session, recovering from a midday dip amid positive sentiment in the broader market.

20 ago 2026, 20:06 UTC

Pacira Biosciences Inc shares are lower today, continuing a decline from Wednesday's close. The stock remains below its 20-day moving average.

19 ago 2026, 19:46 UTC

Pacira Biosciences Inc. shares are higher today, reflecting a broader market trend amid declining bond yields. The stock remains below its 20-day moving average.

18 ago 2026, 20:03 UTC

Shares of Pacira Biosciences are higher, reflecting broader market strength. The stock remains below its 20-day moving average and near the lower end of its trading range.

17 ago 2026, 19:26 UTC

News

Pacira Biosciences Inc shares are higher following Truist Securities' reinstatement of coverage with a Buy rating and a price target of $30.00.

14 ago 2026, 19:36 UTC

Pacira Biosciences Inc shares are lower, marking the seventh consecutive decline. Broader market sentiment is affected by a reported drop in retail sales for July.

13 ago 2026, 20:06 UTC

Pacira Biosciences Inc shares fell during Thursday's session, continuing a trend of declines and remaining below the 20-day moving average. No specific news was identified.

12 ago 2026, 20:01 UTC

Pacira Biosciences Inc's shares are lower today, continuing a downward trend with a cumulative return of -3.36% since Tuesday. No specific news was identified.

11 ago 2026, 19:16 UTC

Shares of Pacira Biosciences Inc. are lower today, continuing a trend of three consecutive declines. The stock is trading below its 20-day moving average.

10 ago 2026, 19:36 UTC

Pacira Biosciences Inc is trading lower, continuing a decline since Friday. The stock remains below its 20-day moving average amid broader market volatility.

7 ago 2026, 20:02 UTC

Event

Pacira Biosciences shares are lower despite positive two-year Phase 1 trial results for PCRX-201, an investigational gene therapy for knee osteoarthritis.

6 ago 2026, 19:52 UTC

News
Event

Pacira Biosciences Inc. shares are higher following positive two-year results from its Phase 1 trial for PCRX-201, a gene therapy for knee osteoarthritis.

5 ago 2026, 20:03 UTC

News

Pacira Biosciences reported improved earnings but lowered its 2026 revenue guidance, contributing to a decline in shares since Tuesday's close.

4 ago 2026, 19:53 UTC

Pacira Biosciences Inc is higher today, supported by overall market strength and a decline in crude oil prices easing inflation concerns.

3 ago 2026, 20:06 UTC

Pacira Biosciences Inc. shares are higher today, reflecting broader market gains led by major stocks, despite no specific company news identified.

31 jul 2026, 20:02 UTC

Pacira Biosciences Inc's shares are lower today, reaching a session low earlier. The price remains above its 20-day moving average despite the decline.

30 jul 2026, 17:16 UTC

Pacira Biosciences is advancing during Thursday's session, regaining momentum after earlier pulling back from a session high amid broader market optimism.

29 jul 2026, 20:04 UTC

Shares of Pacira Biosciences Inc. are lower today, continuing a decline since Tuesday's close. The stock reached an early high before falling significantly.

28 jul 2026, 19:56 UTC

Event
News

Shares of Pacira Biosciences Inc. are higher, driven by survey findings on orthopedic pain's impact on the workforce and strong interest in non-opioid treatments.

27 jul 2026, 18:51 UTC

Event
News

Pacira Biosciences advances PCRX-201 to commercial manufacturing, allowing patient enrollment in Phase 2 ASCEND study. Shares are higher as investor confidence strengthens.

24 jul 2026, 17:16 UTC

Pacira Biosciences Inc shares are lower today, with no specific news driving the decline. Broader market sentiment is impacted by falling crude oil prices.

22 jul 2026, 18:06 UTC

Pacira Biosciences Inc shares are lower in Wednesday's session, pulling back from earlier gains amid broader market caution and rising crude oil prices.

21 jul 2026, 19:56 UTC

Pacira Biosciences Inc is trading higher, reflecting broader market interest in technology and AI sectors ahead of upcoming earnings reports.

20 jul 2026, 19:46 UTC

Pacira Biosciences Inc shares are trading lower today, having retraced from an earlier high. No specific news was identified to explain the decline.

Comparación entre iguales

Cambio de precio

Pacira Pharmaceuticals Inc-DE previsión

Precio Objetivo

By TipRanks

12.81% repunte

Estimación a 12 Meses

Media 28.8 USD  12.81%

Máximo 38 USD

Mínimo 23 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pacira Pharmaceuticals Inc-DE Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

3

Comprar

2

Mantener

1

Vender

Sentimiento

By Acuity

293 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Pacira Pharmaceuticals Inc-DE

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
help-icon Live chat